Furnished
as Exhibit 99.1 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. (the “Company”) dated November 12, 2026, announcing the Company’s results for the three month period ended September 30, 2026.
On November 12, 2026 the Company issued a press release titled, “ProQR Announces Third Quarter 2026 Operating and Financial Results,”
announcing the Company’s results for the three month period ended September 30, 2026 and providing a business update. A copy of
this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference
ProQR hereby incorporates by reference the information contained herein into ProQR's registration statements on Form F-3 (File No. 333-282419,
File No. 333-270943, File No. 333-263166, File No. 333-285767 and File No. 333-297272)
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99. 1
ProQR Announces Third Quarter 2026 Operating
and Financial Results
| · | Fully
enrolled Cohorts 1 and 2 of AX-0811 Phase 1 trial; initial target engagement data expected
in early January 2027 |
| · | Full
AX-0810 Phase 1 dataset, including Cohort 3 and follow-up data, and new AX-0811 preclinical
proof-of-concept data to be presented in December 2026 |
| · | Multiple
clinical milestones expected in H1 of 2027, including initiation of pediatric biliary atresia
IIT, initial AX-0422 patient data in MPS I Hurler syndrome, and advancement of AX-2911 into
the clinic for MASH IIT |
| · | Ended
Q3 2026 with € 103 million cash and cash equivalents, supporting runway into mid-2028 |
LEIDEN, Netherlands & CAMBRIDGE,
Mass., November 12, 2026 – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives
through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial
and operating results for the third quarter ended September 30, 2026, and provided a business update.
“Having established the first
clinical validation of our Axiomer RNA editing platform, we are now expanding our pipeline on that foundation through several other programs
that are entering clinical development,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “The Phase
1 study of AX-0811 has now fully enrolled its first two cohorts. AX-0811 is our next-generation editing oligonucleotide targeting NTCP
for cholestatic diseases, including biliary atresia. We also strengthened our AI capabilities through the appointment of Chris Hart as
Chief Data and AI Officer and Thomas Wolf to our Board as a strategic AI advisor.”
De Boer continued, “We expect
to report initial AX-0811 data in early January 2027 and look forward to presenting the full AX-0810 Phase 1 dataset, including Cohort
3, in December 2026. We expect these data to be followed by a series of additional clinical milestones across our pipeline in the first
half of 2027, including initiation of our biliary atresia clinical program, initial patient data from AX-0422 in MPS I Hurler syndrome,
and advancement of AX-2911 for MASH into the clinic. Across these programs, our focus remains on developing RNA editing therapies that
can make a meaningful difference for patients and their families.”
Recent Progress and Anticipated
Upcoming Events
Clinical Development Progress with
NTCP Programs
Following the positive AX-0810 Phase
1 target engagement data reported in June 2026, ProQR expects to present the full dataset, including Cohort 3 and 12-week follow up,
at the Nature Conferences RNA at the Bench and Bedside V meeting in December 2026.
In September 2026, ProQR announced the
dosing of the first participant in the Phase 1 clinical trial of AX-0811, the Company’s next-generation editing oligonucleotide
targeting NTCP, which was identified through ProQR’s AI-enabled discovery engine. The first two cohorts of healthy volunteers are
now fully enrolled, with initial AX-0811 Phase 1 target engagement data expected in early January 2027. The study is evaluating the safety,
tolerability, pharmacokinetics, and pharmacodynamic effects via biomarker-based target engagement. AX-0811 preclinical data demonstrate
greater potency and a longer half-life compared with AX-0810, with the potential for lower dose levels and less frequent dosing in the
clinic.
In September 2026, the Company hosted
a virtual educational event focused on NTCP modulation in biliary atresia through liver-targeted RNA editing. The event
featured ProQR management and Professor Gideon Hirschfield of the Toronto Centre for Liver Disease and provided an overview of bile acid
biology, NTCP modulation, translational rationale and clinical development strategy for RNA editing NTCP modulation in biliary atresia.
The event outlined the framework for evaluating upcoming AX-0811 Phase 1 target engagement data:
| · | TUDCA
is expected to be the most sensitive measure for comparing pharmacodynamic effects, |
| · | Conjugated
bile acid profile will be informative for assessing translation into the disease setting,
and |
| · | Total
bile acids in serum provides an additional supportive measure of target engagement. |
Based on preclinical data, ProQR expects
AX-0811 to outperform AX-0810 across all three biomarkers in equivalent cohorts.
ProQR is also continuing preparations
for an investigator-initiated trial (IIT) in pediatric biliary atresia in China, with initial clinical data expected in the first half
of 2027.
Conference Presentations
In November 2026, ProQR participated
in TIDES Europe and The Liver Meeting 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD),
where presentations highlighted previously disclosed AX-0810 clinical findings and preclinical data for AX-0811.
Strengthening AI and Data Capabilities
In September 2026, ProQR appointed Chris
Hart, PhD, as Chief Data and AI Officer. Dr. Hart most recently served as Vice President of Data Science and AI/ML for Genetic Medicines
at Eli Lilly and Company and has more than 15 years of experience applying AI/ML to oligonucleotide therapeutics. ProQR also announced
in September that Thomas Wolf, PhD, co-founder and Chief Scientific Officer of Hugging Face, has joined ProQR’s Board of Directors
as a strategic AI advisor.
Upcoming anticipated milestones
NTCP
programs
| · | AX-0810
data from the 9 mg/kg cohort and 12-week follow up from the ongoing Phase 1 study and new
preclinical data for AX-0811 expected in December 2026 |
| · | AX-0811
initial target engagement data from Cohorts 1 and 2 in healthy volunteers expected in early
January 2027 |
| · | IIT
in pediatric biliary atresia in China, with initiation and initial data targeted for the
first half of 2027 |
| · | Potentially
registration-enabling Phase 2 program, subject to regulatory interactions, expected to start
in mid-2027 with first interim analysis data expected by mid-2028 |
Other pipeline
candidates
| · | AX-0422
for MPS I Hurler Syndrome (IDUA) CTA filing for a first-in-patient study anticipated in early
2027 and initial data expected in the first half of 2027 |
| · | AX-2911
(PNPLA3) FIH IIT in China expected in the first half of 2027 |
Partnership
| · | Continue
to execute on Lilly collaboration, with potential data updates and milestone payments |
Financial Highlights
At September 30, 2026, ProQR held cash
and cash equivalents of approximately € 103.0 million, compared to € 92.4 million at December 31, 2025.
Net cash used in operating activities
during the third quarter ended September 30, 2026 was € 13.6 million, compared to € 12.2 million used for the same period in
2025.
Research and development (R&D) costs
for the quarter ended September 30, 2026 were € 14.3 million, compared to € 11.1 million for the same period last year.
General and administrative costs for
the quarter ended September 30, 2026 were € 4.0 million, compared to € 3.1 million for the same period in 2025.
Net loss for the quarter ended September
30, 2026 was € 12.4 million, or € 0.09 per diluted share, compared to € 11.0 million, or € 0.10 per diluted share,
for the same period in 2025.
For further financial information for
the period ended September 30, 2026, please refer to our Q3 financial report filing available on our website, www.proqr.com under
Financials and Filings.
About Axiomer™
ProQR is pioneering a next-generation
RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types
of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a
highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on
RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an
Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation
back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps
prevent or treat disease.
About ProQR
ProQR Therapeutics is a clinical-stage
company dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology
called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits
in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent
diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients
and loved ones in mind.
Learn more about ProQR at www.proqr.com.
Forward Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms
such as “continue,” "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential," "predict,"
"project," "should," "will," "would" and similar expressions. Such forward-looking statements
include, but are not limited to, statements regarding our business, technology, strategy, preclinical and clinical model data; our initial
pipeline targets and the upcoming strategic priorities and milestones related thereto; the continued advancement of our lead development
pipeline programs, including ongoing and planned clinical trials; the ongoing Phase 1 clinical study of AX-0810 targeting NTCP for cholestatic
diseases, including the timing and presentation of the full Phase 1 dataset, including Cohort 3 and 12-week follow-up data, in December
2026 at the Nature Conferences RNA at the Bench and Bedside V meeting and the presentation of new preclinical data for AX-0811; our expectations
regarding the safety, tolerability, target engagement and potential therapeutic benefits of AX-0810; our ability to collaborate with
investigators to initiate, conduct and recruit for an IIT of our NTCP program in China in pediatric participants with biliary atresia
and to generate meaningful data therefrom, including the anticipated timing of initial data readout in the first half of 2027; the anticipated
initiation of our potentially registration-enabling Phase 2 program in mid-2027 with first interim analysis data expected by mid-2028,
subject to regulatory interactions; our pipeline targets, including the ongoing Phase 1 clinical trial of AX-0811 in healthy volunteers;
our ability to continue to enroll and complete the ongoing Phase 1 clinical trial for AX-0811 and the anticipated timing of initial data
readout expected in early January 2027; the anticipated first-in-patient study of AX-0422 targeting IDUA for MPS I Hurler syndrome, with
a CTA filing expected in early 2027 and anticipated initial clinical data readout in the first half of 2027; the anticipated IIT in China
of AX-2911 targeting PNPLA3 for MASH in the first half of 2027; our expectations regarding clinical updates across multiple programs
in 2026 and 2027; the potential design, initiation and timing of a potentially registration-enabling Phase 2 program for the NTCP franchise,
subject to regulatory interactions; the therapeutic potential and development timeline regarding AX-0810, AX-0811, AX-0422, and AX-2911;
our participation at upcoming scientific conferences; the continued development and advancement of our Axiomer platform and our AI-enabled
discovery engine, and the anticipated benefits of our AI and data capabilities; the therapeutic potential of our Axiomer RNA editing
oligonucleotides and product candidates; the timing, progress and results of our preclinical studies and other development and pipeline
activities, including the release of data related thereto; our patent estate, including its anticipated strength and our continued investment
in it, as well as the timing of our clinical development; the potential of our technologies and product candidates; the collaboration
with Lilly and the intended benefits thereof, including timing for data updates, and potential milestones; and our financial position
and expected cash runway to fund our operations into mid-2028. Forward-looking statements are based on management's beliefs and assumptions
and on information available to management only as of the date of this press release. Our actual results could differ materially from
those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties
and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual
report filed on Form 20-F. These risks and uncertainties include, among others, risks and uncertainties associated with conducting IITs
in China, including evolving regulatory requirements, the cost, timing and results of preclinical studies and clinical trials and other
development activities by us and our collaborative partners whose operations and activities may be slowed or halted due to shortage and
pressure on supply chains and logistics in the global market, economic sanctions and international tariffs; the likelihood of our preclinical
and clinical programs being initiated and executed on timelines provided and our reliance on our contract research organizations and
predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance
on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer;
the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration
and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress
our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the
collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible
safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial
and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions
and market volatility resulting from global economic developments, geopolitical events and conflicts, inflationary pressures, fluctuating
interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties
and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor
and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Financial Position
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| | |
€1,000 | | |
€1,000 | |
| Assets | |
| | | |
| | |
| Property, plant and equipment | |
| 11,046 | | |
| 12,630 | |
| Investments in financial assets | |
| — | | |
| — | |
| Non-current assets | |
| 11,046 | | |
| 12,630 | |
| | |
| | | |
| | |
| Cash and cash equivalents | |
| 102,986 | | |
| 92,413 | |
| Trade and other receivables | |
| 4,285 | | |
| 6,800 | |
| Other taxes | |
| 781 | | |
| 913 | |
| Current assets | |
| 108,052 | | |
| 100,126 | |
| Total assets | |
| 119,098 | | |
| 112,756 | |
| | |
| | | |
| | |
| Equity and liabilities | |
| | | |
| | |
| Equity | |
| | | |
| | |
| Equity attributable to owners of the Company | |
| 68,184 | | |
| 49,374 | |
| Total equity | |
| 68,184 | | |
| 49,374 | |
| | |
| | | |
| | |
| Liabilities | |
| | | |
| | |
| Borrowings | |
| — | | |
| — | |
| Lease liabilities | |
| 7,790 | | |
| 9,547 | |
| Deferred income | |
| 9,422 | | |
| 21,394 | |
| Non-current liabilities | |
| 17,212 | | |
| 30,941 | |
| | |
| | | |
| | |
| Borrowings | |
| 5,090 | | |
| 4,872 | |
| Lease liabilities | |
| 1,692 | | |
| 1,545 | |
| Derivative financial instruments | |
| 183 | | |
| 234 | |
| Trade payables | |
| 2,564 | | |
| 298 | |
| Social securities and other taxes | |
| 102 | | |
| — | |
| Deferred income | |
| 13,578 | | |
| 17,552 | |
| Other current liabilities | |
| 10,493 | | |
| 7,940 | |
| Current liabilities | |
| 33,702 | | |
| 32,441 | |
| Total liabilities | |
| 50,914 | | |
| 63,382 | |
| | |
| | | |
| | |
| Total equity and liabilities | |
| 119,098 | | |
| 112,756 | |
PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
(€ in thousands, except share and
per share data)
| | |
Three month period | | |
Nine month period | |
| | |
ended September 30, | | |
ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
€1,000 | | |
€1,000 | | |
€1,000 | | |
€1,000 | |
| Revenue | |
| 5,155 | | |
| 2,882 | | |
| 15,947 | | |
| 11,218 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other income | |
| — | | |
| 33 | | |
| — | | |
| 413 | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development costs | |
| (14,323 | ) | |
| (11,080 | ) | |
| (38,820 | ) | |
| (34,811 | ) |
| General and administrative costs | |
| (3,967 | ) | |
| (3,119 | ) | |
| (12,733 | ) | |
| (11,169 | ) |
| Total operating costs | |
| (18,290 | ) | |
| (14,199 | ) | |
| (51,553 | ) | |
| (45,980 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Operating result | |
| (13,135 | ) | |
| (11,284 | ) | |
| (35,606 | ) | |
| (34,349 | ) |
| Finance income and expense | |
| 658 | | |
| 280 | | |
| 1,022 | | |
| 927 | |
| Results related to financial liabilities measured at fair value through profit or loss | |
| 30 | | |
| (2 | ) | |
| 51 | | |
| 176 | |
| | |
| | | |
| | | |
| | | |
| | |
| Result before corporate income taxes | |
| (12,447 | ) | |
| (11,006 | ) | |
| (34,533 | ) | |
| (33,246 | ) |
| Income taxes | |
| — | | |
| — | | |
| (25 | ) | |
| (18 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Result for the period | |
| (12,447 | ) | |
| (11,006 | ) | |
| (34,558 | ) | |
| (33,264 | ) |
| Other comprehensive income (foreign exchange differences on foreign operation) | |
| 28 | | |
| (23 | ) | |
| 255 | | |
| (1,076 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Total comprehensive income | |
| (12,419 | ) | |
| (11,029 | ) | |
| (34,303 | ) | |
| (34,340 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Result attributable to | |
| | | |
| | | |
| | | |
| | |
| Owners of the Company | |
| (12,447 | ) | |
| (11,006 | ) | |
| (34,558 | ) | |
| (33,264 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Total comprehensive income attributable to | |
| | | |
| | | |
| | | |
| | |
| Owners of the Company | |
| (12,419 | ) | |
| (11,029 | ) | |
| (34,303 | ) | |
| (34,340 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Share information | |
| | | |
| | | |
| | | |
| | |
| Weighted average number of shares outstanding1 | |
| 141,231,466 | | |
| 105,344,996 | | |
| 118,982,158 | | |
| 105,328,752 | |
| | |
| | | |
| | | |
| | | |
| | |
| Earnings per share attributable to owners of the Company (Euro per share) | |
| | | |
| | | |
| | | |
| | |
| Basic loss per share1 | |
| (0.09 | ) | |
| (0.10 | ) | |
| (0.29 | ) | |
| (0.32 | ) |
| Diluted loss per share1 | |
| (0.09 | ) | |
| (0.10 | ) | |
| (0.29 | ) | |
| (0.32 | ) |
| 1. | For
these periods the potential exercise of share options is not included in the diluted earnings
per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding
options, basic and diluted earnings per share are equal. |
PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Changes in Equity
| | |
Attributable to owners of the Company | |
| | |
Number
of shares | |
Share
Capital | |
Share
Premium | |
Equity settled
Employee
Benefit
Reserve | |
Translation
Reserve | |
Accumulated
Deficit | |
Total
Equity | |
| | |
| |
€1,000 | |
€1,000 | |
€1,000 | |
€1,000 | |
€1,000 | |
€1,000 | |
| Balance at January 1, 2025 | |
107,710,916 | |
| 4,308 | |
| 483,812 | |
| 26,248 | |
| 1,350 | |
| (427,158 | ) |
| 88,560 | |
| Result for the period | |
— | |
| — | |
| — | |
| — | |
| — | |
| (33,264 | ) |
| (33,264 | ) |
| Other comprehensive income | |
— | |
| — | |
| — | |
| — | |
| (1,076 | ) |
| — | |
| (1,076 | ) |
| Recognition of share-based payments | |
— | |
| — | |
| — | |
| 2,784 | |
| — | |
| — | |
| 2,784 | |
| Treasury shares transferred | |
(132,665 | ) |
| — | |
| — | |
| — | |
| — | |
| — | |
| — | |
| Share options lapsed | |
— | |
| — | |
| — | |
| (1,532 | ) |
| — | |
| 1,532 | |
| — | |
| Share options exercised / RSUs vested | |
132,665 | |
| — | |
| 67 | |
| (184 | ) |
| — | |
| 184 | |
| 67 | |
| | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| Balance at September 30, 2025 | |
107,710,916 | |
| 4,308 | |
| 483,879 | |
| 27,316 | |
| 274 | |
| (458,706 | ) |
| 57,071 | |
| | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| Balance at January 1, 2026 | |
107,710,916 | |
| 4,308 | |
| 483,881 | |
| 28,426 | |
| 265 | |
| (467,506 | ) |
| 49,374 | |
| Result for the period | |
— | |
| — | |
| — | |
| — | |
| — | |
| (34,558 | ) |
| (34,558 | ) |
| Other comprehensive income | |
— | |
| — | |
| — | |
| — | |
| 255 | |
| — | |
| 255 | |
| Recognition of share-based payments | |
— | |
| — | |
| — | |
| 3,955 | |
| — | |
| — | |
| 3,955 | |
| Issuance of ordinary shares | |
35,755,393 | |
| 1,430 | |
| 47,478 | |
| — | |
| — | |
| — | |
| 48,908 | |
| Treasury shares transferred | |
(212,754 | ) |
| — | |
| — | |
| — | |
| — | |
| — | |
| — | |
| Share options lapsed | |
— | |
| — | |
| — | |
| (2,428 | ) |
| — | |
| 2,428 | |
| — | |
| Share options exercised / RSUs vested | |
212,754 | |
| — | |
| 250 | |
| (298 | ) |
| — | |
| 298 | |
| 250 | |
| | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| Balance at September 30, 2026 | |
143,466,309 | |
| 5,738 | |
| 531,609 | |
| 29,655 | |
| 520 | |
| (499,338 | ) |
| 68,184 | |
PROQR THERAPEUTICS N.V.
Unaudited Interim Condensed Consolidated Statement of Cash Flows
| | |
Three month period | | |
Nine month period | |
| | |
ended September 30, | | |
ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
€1,000 | | |
€1,000 | | |
€1,000 | | |
€1,000 | |
| Cash flows from operating activities | |
| | | |
| | | |
| | | |
| | |
| Net result | |
| (12,447 | ) | |
| (11,006 | ) | |
| (34,558 | ) | |
| (33,264 | ) |
| Adjustments for: | |
| | | |
| | | |
| | | |
| | |
| — Other income | |
| — | | |
| (33 | ) | |
| — | | |
| (413 | ) |
| — Depreciation | |
| 777 | | |
| 671 | | |
| 2,178 | | |
| 2,024 | |
| — Share-based compensation | |
| 1,169 | | |
| 1,117 | | |
| 3,955 | | |
| 2,784 | |
| — Financial income and expenses | |
| (706 | ) | |
| (280 | ) | |
| (1,075 | ) | |
| (927 | ) |
| — Results related to financial liabilities measured at fair value through profit or loss | |
| (30 | ) | |
| 2 | | |
| (51 | ) | |
| (176 | ) |
| — Income tax expenses | |
| — | | |
| — | | |
| 25 | | |
| 18 | |
| | |
| | | |
| | | |
| | | |
| | |
| Changes in working capital | |
| (2,961 | ) | |
| (3,074 | ) | |
| (8,606 | ) | |
| (10,974 | ) |
| Cash used in operations | |
| (14,198 | ) | |
| (12,603 | ) | |
| (38,132 | ) | |
| (40,928 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Corporate income tax paid | |
| — | | |
| — | | |
| (25 | ) | |
| (18 | ) |
| Interest received | |
| 740 | | |
| 519 | | |
| 1,466 | | |
| 1,924 | |
| Interest paid | |
| (128 | ) | |
| (151 | ) | |
| (310 | ) | |
| (412 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net cash used in operating activities | |
| (13,586 | ) | |
| (12,235 | ) | |
| (37,001 | ) | |
| (39,434 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Cash flow from investing activities | |
| | | |
| | | |
| | | |
| | |
| Purchases of property, plant and equipment | |
| (354 | ) | |
| (169 | ) | |
| (809 | ) | |
| (494 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net cash used in investing activities | |
| (354 | ) | |
| (169 | ) | |
| (809 | ) | |
| (494 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Cash flows from financing activities | |
| | | |
| | | |
| | | |
| | |
| Proceeds from issuance of shares, net | |
| (293 | ) | |
| — | | |
| 48,908 | | |
| — | |
| Proceeds from exercise of share options | |
| 250 | | |
| — | | |
| 250 | | |
| 67 | |
| Repayment of lease liability | |
| (300 | ) | |
| (444 | ) | |
| (1,225 | ) | |
| (1,304 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net cash (used in) / generated by financing activities | |
| (343 | ) | |
| (444 | ) | |
| 47,933 | | |
| (1,237 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net (decrease) / increase in cash and cash equivalents | |
| (14,283 | ) | |
| (12,848 | ) | |
| 10,123 | | |
| (41,165 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Currency effect cash and cash equivalents | |
| 144 | | |
| (34 | ) | |
| 450 | | |
| (1,360 | ) |
| Cash and cash equivalents, at beginning of the period | |
| 117,125 | | |
| 119,765 | | |
| 92,413 | | |
| 149,408 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cash and cash equivalents at the end of the period | |
| 102,986 | | |
| 106,883 | | |
| 102,986 | | |
| 106,883 | |
